November 29, 2021

Associations between diet and ADHD emerge from Swedish population-based twin study

Sweden has a national single-payer health insurance system that includes virtually the entire population. It also has a system of national registers that track every resident from birth to death. That makes it possible to conduct nationwide population studies with a very high degree of precision and reliability.

In addition, one of the national registers is the Swedish Twin Register. Tracking all twins in the population enables studies to evaluate the degree to which observed associations may be attributable to genetic influences and to familial confounding. The twin method relies on the different levels of genetic relatedness between monozygotic ("identical") twins, who are genetically identical, and dizygotic ("fraternal") twins, who share on average half of their genetic variation (as do ordinary full siblings).

A Swedish team of researchers identified 42,582 Swedish twins born between 1959 and 1985, and who were, therefore, adults by the time of the study (20-47 years old). Of these, 24,872 (three out of five) completed a web-based survey with 1,300 questions covering lifestyle and mental and physical health. Out of this group, 17,999 provided information on ADHD symptoms and food frequency.

Self-reported ADHD symptoms came from nine inattention components and nine hyperactivity/impulsivity components, covering the 18 DSM- IV symptoms of ADHD.

The food frequency questionnaire included 94 food items, with the following frequency categories: never, 1-3 times/month, 1-2 times/week, 3-4 times/week, 5-6 times/week, 1 time/day, 2 times/day, 3 times/day.

In the raw data, the two subtypes of ADHD exhibited very similar associations. Both had significant associations with unhealthy diets. Both were more likely to be eating foods high in added sugar, and neglecting fruits and vegetables while eating more meat and fats.

After adjusting for the degree of relatedness of twins (whether monozygotic or dizygotic) and controlling for the other ADHD subtype, the associations remained statistically significant for inattention, but diminished to negligible levels or became statistically non-significant for hyperactivity/impulsivity.

Even for persons with inattention symptoms, adjusted correlations were small (never exceeding r = 0.10), with the strongest associations being for overall unhealthy eating habits (r = 0.09), eating foods high in added sugar (r = 0.10) or high in fat (r = 0.05), and neglecting fruits and vegetables (r = 0.06). All other associations became statistically non-significant.

For persons with hyperactivity/impulsivity symptoms, the only associations that remained statistically significant ­- but at tiny effect sizes - were unhealthy dietary patterns (r = 0.04) and consumption of foods high in added sugar (r = 0.03).

The further genetic analysis, therefore, focused on the strongest associations, between ADHD subtypes on the one hand, and unhealthy dietary patterns and eating foods high in added sugar on the other hand. The heritability estimates (the fraction of phenotypic covariance explained by genetic influences) were 44%, 40%, and 37% for inattention and high-sugar food, inattention and unhealthy dietary patterns, and hyperactivity/impulsivity and high-sugar food, respectively.

 When examining only differences between pairs of monozygotic("identical") twins, the correlations became stronger for inattention, rising to r = 0.12 for unhealthy eating habits and r = 0.13 for consumption of foods high in added sugar. For hyperactivity/impulsivity symptoms, the association with unhealthy eating habits was weaker, and the association with consumption of foods high in added sugar became statistically insignificant.

The authors concluded, "we identified positive associations between self-reported trait dimensions of ADHD and intake of seafood, high-fat food, high-sugar food, high-protein food, and an unhealthy dietary pattern, and negative associations with consumption of fruits, vegetables, and a healthy dietary pattern. However, all the associations are small in magnitude. These associations were stronger for inattention compared to hyperactivity/ impulsivity. This pattern of associations was also reflected at the etiological level, where we found a slightly stronger genetic correlation between inattention with dietary habits and hyperactivity/impulsivity with dietary habits. Non-shared environmental influences also contributed to the overlap between ADHD symptom dimensions and consumption of high-sugar food and unhealthy dietary pattern. However, shared environmental influences probably contributed relatively little to the associations between ADHD symptoms and dietary habits. ... significant MZ twin intraplate differences also provided support for a potential causal link between inattention and dietary habits.

Lin Li, Mark J. Taylor, Katarina Bälter, Ralf Kuja-Halkola, Qi Chen, Tor-Arne Hegvik, Ashley E. Tate, Zheng Chang, Alejandro Arias-Vásquez, Catharina A. Hartman, Henrik Larsson, "Attentiondeficit/hyperactivity disorder symptoms and dietary habits in adulthood: A large populationbased twin study in Sweden," American Journal of Medical Genetics (2020) Vol.183, Issue 8, 475-485, https://doi.org/10.1002/ajmg.b.32825.

Related posts

No items found.

Swedish Nationwide Population Study: Little ADHD Risk from Vacuum-Assisted Delivery

Vacuum-assisted delivery (VAD), also called vacuum extraction, is an assisted vaginal birth method in which a soft plastic cup is attached to the baby’s head with suction to help guide the infant through the birth canal during the pushing stage. Clinicians typically use VAD when labor stalls, the mother is exhausted, or there are concerns about the baby’s heart rate. It is an alternative to a cesarean section (C‑section) that can avoid major surgery. 

In Sweden, VAD is used in about 6%–9% of births, while forceps deliveries are uncommon. When performed with the fetal head at the outlet station (very low in the birth canal), VAD is usually quick and carries minimal risk of injury in full-term babies; these outlet procedures make up roughly half of all VADs. By contrast, several studies have linked VAD performed at mid or low fetal head stations with more serious neonatal complications, such as intracranial bleeding, seizures and, in rare cases, death. 

Despite concerns about short-term neonatal injury after mid/low VAD, research on long-term neurodevelopmental outcomes is limited. A few more recent studies have not found clear links between VAD and adverse long-term outcomes, but most of those studies did not separate outlet from mid/low procedures. 

To address this gap, the authors conducted a nationwide, population-based study in Sweden to compare neonatal and long-term neurodevelopmental outcomes after VAD, and to stratify results by fetal station. They included emergency cesarean delivery and spontaneous vaginal delivery as reference groups to help interpret outcomes after VAD. 

The study used Sweden’s linked national registers, possible because every resident has a personal identification number. Sweden’s tax-funded single-payer health system and nearly universal hospital births mean the registers provide comprehensive, standardized data suitable for long-term follow-up. 

The cohort comprised 630,985 singleton term births from 1997 through 2014. Of these, 73,215 (11.6%) were delivered by VAD, 73,739 (11.7%) by emergency cesarean delivery, and 484,031 (76.7%) by spontaneous vaginal delivery. Among the VAD births, 31,014 (42.4%) were classified as mid/low station and 42,201 (57.6%) as outlet VAD. 

The investigators adjusted their analyses for potential confounders including maternal age; early-pregnancy body-mass index; smoking during pregnancy; the child’s birth year; preeclampsia; gestational diabetes; chorioamnionitis; maternal education level; and maternal medical or psychiatric conditions (type 1 or type 2 diabetes, ADHD, autism spectrum disorder, depression and anxiety). 

After adjustment, VAD overall was associated with a 6% lower risk of later being diagnosed with ADHD compared with the reference groups. When broken down by fetal station, mid/low VAD showed no difference in ADHD risk, while outlet VAD was associated with a 9% lower risk. For comparison, spontaneous vaginal delivery was associated with a 12% lower risk of later ADHD. 

The authors concluded that, in this large nationwide cohort, the findings may offer reassuring evidence about the overall long-term neurodevelopmental safety of VAD.  

‍

‍

‍

Meta-analysis: Almost Three in Four ADHD Patients Receive Pharmaceutical Treatment

The Background:

Management of ADHD relies on both medications and non-medication approaches. Clinical guidelines often recommend medication as the first-line treatment for adults, while non-medication interventions are often preferred for children. Medicines fall into two main groups: stimulants (for example, methylphenidate and amphetamines), which have strong and well-established evidence and are generally considered first choice, and non-stimulants (such as atomoxetine), which are typically used when stimulants are contraindicated, not tolerated, or ineffective. 

How many people with ADHD receive medication is an important indicator of care quality and can be tracked at the national level. Untreated ADHD can affect many areas of life, from physical health, to school and work performance, to relationships emotional well-being. ADHD is associated with poorer quality of life, higher risk of accidents, substance use issues, criminal behavior, educational underachievement, and even increased premature mortality. The condition also places a substantial burden on families and caregivers, so understanding treatment rates matters for individuals and society. 

Most epidemiological research has measured how common diagnosed ADHD is, but the share of those diagnosed who actually receive medication can vary a lot. That variation reflects differences in how ADHD is diagnosed, how easy it is to get treatment, what clinical guidelines recommend, and cultural attitudes toward using medication. 

The Study:

This paper presents the first comprehensive meta-analysis to estimate how common pharmacological treatment is among children, adolescents, and adults with clinically confirmed ADHD. The analysis included only register-based population studies where diagnoses were confirmed by a qualified healthcare professional. Twelve studies meeting these criteria from Europe (the UK, Sweden, Denmark), Asia (Taiwan, South Korea), and North America (Canada, the United States) were used. Notably, these are all high-income areas, and thus unrepresentative of populations in lower-income countries.  

The pooled estimate showed that about 73 percent of diagnosed individuals in prosperous parts of the world with well-developed health care systems were receiving medication, but there was very high variation between studies. 

The Results:

The authors conclude there is substantial global variation in ADHD medication use. Overall, a relatively high proportion of people diagnosed with ADHD are treated with medication, which may reflect improved recognition and access to care. The large differences between studies probably reflect differing health systems, diagnostic rules, treatment definitions, study populations, and reporting practices, and they underline the need for more standardized definitions and reporting to make comparisons more meaningful.  

There is also a need for information from lower-income regions, but that is complicated by an absence of register-based population studies in countries with more limited health care access.

‍

November 4, 2026

Meta-analysis Finds Three- to Eight-fold Higher ADHD Prevalence Among Adults with Substance Use Disorders

The Background:

Because impulsivity is a core feature of ADHD, researchers have suggested it may raise the likelihood that someone will use psychoactive substances (including alcohol) and go on to develop a substance use disorder (SUD). When ADHD and SUD occur together in adolescents, treating one disorder alone usually has little or no positive effect on the other; current guidance therefore recommends treating both conditions at the same time using evidence-based approaches for each. 

Given how much ADHD can worsen outcomes for people with primary SUDs, it is important to identify ADHD in people who are being treated for substance problems. 

The Study:

A recent systematic meta-review found that, by current official criteria, ADHD affects about 7.2% of children and adolescents and about 2.6% of adults (Chaulagain et al., 2023). When adult ADHD is defined without the requirement that symptoms began by age 11, roughly 6.8% of adults meet criteria. A large body of research links ADHD to higher rates of medical problems, poorer quality of life, greater risk of suicide, more accidental injuries, worse educational outcomes, and increased involvement with the criminal justice system. 

The present study is the first meta-analysis to estimate how common clinically diagnosed ADHD is among adults (age 18+) who are in treatment for psychoactive substance use disorders, and to provide those estimates by sex and by the specific substance used. 

The authors included only studies of adults treated for a SUD (including alcohol). Eighty-four studies met the criteria, representing more than 34,000 people. Across all studies, the pooled prevalence of clinically diagnosed ADHD was 22%. 

To put that in context, 22% is about eight times higher than the 2.6% adult prevalence using the stricter official definition, and about three times higher than the 6.8% rate when the childhood-onset requirement is relaxed. By substance, the prevalence was similar for alcohol (24%) and opioids (22%), with no significant difference between males and females. Prevalence among people treated for cocaine use was somewhat lower overall (18%), driven largely by lower rates among women, for whom the rate was no higher than in the general population. Estimates were higher for people using benzodiazepines and cannabis, but those figures are based on a very small number of users (256 and 249 people, respectively) and are therefore less certain. 

The Results: 

The authors conclude: “These findings underscore the need for early identification and treatment of ADHD as most substance use disorders develop in adolescence and young adulthood. While in treatment for ADHD, appropriate screening and management of substance use is possible.” 

‍

October 29, 2026